

**K192815 Elecsys BRAHMS PCT**Mar 9, 2020  
160 days to decisionK192815 · Product code: **PRI** · Microbiology  
Source: <https://www.510kdatabase.net/k192815/>**SUBMISSION DETAILS**

---

|                       |                                    |
|-----------------------|------------------------------------|
| Decision              | Substantially Equivalent (Cleared) |
| Submission type       | Traditional                        |
| Device classification | Procalcitonin Assay (PRI)          |
| Date received         | Oct 1, 2019                        |
| Decision date         | Mar 9, 2020                        |
| Days to decision      | 160 days                           |
| Third-party review    | No                                 |
| Combination product   | No                                 |
| PCCP authorized       | No                                 |
| Summary / Statement   | Summary                            |

**APPLICANT**

---

|                |   |
|----------------|---|
| Company        | <b>Roche Diagnostics</b>  |
| Location       | Indianapolis, IN, US  |
| Contact        | Wes Gerbig  |
| Website        | <a href="https://diagnostics.roche.com">https://diagnostics.roche.com</a> |
| 510(k) history | 182 submissions · 180 cleared · 2005-2026                                 |

Roche Diagnostics is a Swiss multinational healthcare company specializing in diagnostic devices and solutions. The company operates its U.S. diagnostics division from Indianapolis. Roche Diagnostics maintains a strong FDA 510(k) regulatory record with FDA 510(k) cleared devices from total submissions since 2005. The company's portfolio spans chemistry devices, immunology assays, microbiology testing, and hematology systems. The latest clearance in 2026 reflects continued innovation and regulatory engagement. Recent cleared devices include glucose monitoring systems, elec...